Groowe Groowe / Newsroom / ALVO
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ALVO News

Alvotech Ordinary Shares

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

globenewswire.com
ALVO

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alvotech (ALVO) and Encourages Stockholders to Learn More About the Investigation

accessnewswire.com
ALVO

Investigation Alert: Alvotech (ALVO) Under Scrutiny - Contact Levi & Korsinsky For Details

accessnewswire.com
ALVO

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

globenewswire.com
ALVO

Alvotech kynnir afkomu fyrstu níu mánaða ársins og ræðir nýjustu áfanga í rekstri félagsins þann 13. nóvember nk.

globenewswire.com
ALVO

Alvotech Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm's Investigation

accessnewswire.com
ALVO

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

globenewswire.com
ALVO

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

globenewswire.com
ALVO

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

globenewswire.com
ALVO

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

globenewswire.com
ALVO